Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.

摘要: Introduction The dichotomization of non-small cell carcinoma (NSCLC) subtype into squamous (SQCC) and adenocarcinoma (ADC) has become important in recent years is increasingly required with regard to management. aim this study was determine the utility a panel commercially available antibodies refining diagnosis on small biopsies also whether cytologic material suitable for somatic EGFR genotyping prospectively analyzed series patients undergoing investigation suspected lung cancer. Methods Thirty-two consecutive cases NSCLC were first tested using comprising cytokeratin 5/6, P63, thyroid transcription factor-1, 34²E12, D-PAS stain mucin, their value NSCLC. After test phase, two further pathologists independently reviewed refined that excluded 34²E12 because its low specificity SQCC, refinement concordance assessed. Ten ADC, including eight derived from samples, sent mutation analysis. Results There 65% either SQCC or ADC phase. This included 10 13 where pellets had been prepared transbronchial needle aspirates. Validation by varying expertise pathology confirmed increased diagnosis. All samples adequate analysis, they all showed wild-type genotype. Conclusion A mucin increases diagnostic accuracy agreement between when faced ADC. These even aspirates, seem be